Terms: = Endocrine gland cancer AND PR, PGR, progesterone receptor AND Prognosis
212 results:
1. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract] [Full Text] [Related]
2. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
4. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
5. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract] [Full Text] [Related]
6. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H; Chen C; Wang D; Zhu Y; Chen P
BMC Cancer; 2023 Dec; 23(1):1210. PubMed ID: 38066448
[TBL] [Abstract] [Full Text] [Related]
7. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Donisi G; Nappo G; Pacilli M; Capretti GL; Spaggiari P; Sollai M; Bozzarelli S; Zerbi A
Updates Surg; 2023 Sep; 75(6):1497-1508. PubMed ID: 37578734
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
9. Consolidative radiation in partial responders/unresectable/recurrent disease after first-line/salvage chemotherapy in poor-risk nonseminomatous germ cell tumor prolongs survival: A new paradigm?
Tiwari S; Agrawal S
J Cancer Res Ther; 2023; 19(2):457-460. PubMed ID: 37313917
[TBL] [Abstract] [Full Text] [Related]
10. Primary Ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.
Chen X; Liu HL; Wang JS; Zhao FH
Chin Med Sci J; 2023 Jun; 38(2):130-137. PubMed ID: 37286512
[TBL] [Abstract] [Full Text] [Related]
11. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
Yin M; Lu C; Zhou H; Liu Q; Yang J
BMC Womens Health; 2023 Jun; 23(1):298. PubMed ID: 37270486
[TBL] [Abstract] [Full Text] [Related]
12. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract] [Full Text] [Related]
13. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, Ovarian cancer and Prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
14. Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis.
Su H; Jin Y; Tao C; Yang H; Yang E; Zhang WG; Feng F
J Gynecol Oncol; 2023 Jul; 34(4):e48. PubMed ID: 36998223
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S; Giannone G; Clamp AR; Ennis DP; Glasspool RM; Herbertson R; Krell J; Riisnaes R; Mirza HB; Cheng Z; McDermott J; Green C; Kristeleit RS; George A; Gourley C; Lewsley LA; Rai D; Banerji U; Hinsley S; McNeish IA
JAMA Oncol; 2023 May; 9(5):675-682. PubMed ID: 36928279
[TBL] [Abstract] [Full Text] [Related]
16. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
17. cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Cui M; Shoucair S; Liao Q; Qiu X; Kinny-Köster B; Habib JR; Ghabi EM; Wang J; Shin EJ; Leng SX; Ali SZ; Thompson ED; Zimmerman JW; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; Zheng L; He J; Zhao Y; Wolfgang CL; Yu J
Int J Surg; 2023 Feb; 109(2):99-106. PubMed ID: 36799816
[TBL] [Abstract] [Full Text] [Related]
18. Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K; Nakagawa M; Shimokawa M; Hori K; Tashima L; Goto M; Yanagida S; Suzuki J; Kaya R; Kawabata A; Yamada K; Park J; Nasu H; Nishio S; Kondo E; Kaneda M; Tsubamoto H; Arakawa A; Nagasawa T; Motohashi T
Anticancer Drugs; 2023 Aug; 34(7):857-865. PubMed ID: 36729915
[TBL] [Abstract] [Full Text] [Related]
19. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
[TBL] [Abstract] [Full Text] [Related]
20. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery.
Li X; Liu X; Lu N; Chen Y; Zhang X; Guo C; Xiao W; Xue X; Sun K; Wang M; Gao S; Shen Y; Zhang M; Wu J; Que R; Yu J; Bai X; Liang T
BMC Cancer; 2023 Jan; 23(1):49. PubMed ID: 36641427
[TBL] [Abstract] [Full Text] [Related]
[Next]
